Research programme: GvHD therapeutics - Genmab

Drug Profile

Research programme: GvHD therapeutics - Genmab

Alternative Names: HuMab7D8

Latest Information Update: 10 Oct 2008

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Genmab
  • Class
  • Mechanism of Action CD20 antigen inhibitors; Complement activation stimulants; T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Graft-versus-host disease

Most Recent Events

  • 10 Oct 2008 Discontinued - Preclinical for Graft-versus-host disease in Netherlands (unspecified route)
  • 19 Jan 2006 Preclinical trials in Graft-versus-host disease in Netherlands (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top